MARKET

TGTX

TGTX

Tg Therapeutics Inc
NASDAQ
14.63
+0.48
+3.39%
After Hours: 14.43 -0.2 -1.37% 19:53 01/27 EST
OPEN
14.10
PREV CLOSE
14.15
HIGH
14.85
LOW
13.71
VOLUME
4.00M
TURNOVER
0
52 WEEK HIGH
14.85
52 WEEK LOW
3.480
MARKET CAP
2.13B
P/E (TTM)
-8.2062
1D
5D
1M
3M
1Y
5Y
B.Riley Financial Remains a Buy on TG Therapeutics (TGTX)
TipRanks · 1d ago
H.C. Wainwright Sticks to Its Buy Rating for TG Therapeutics (TGTX)
TipRanks · 1d ago
TG Therapeutics launches newly approved multiple sclerosis therapy
Seeking Alpha · 1d ago
BRIEF-Tg Therapeutics Announces Commercial Launch Of BRIUMVI
Reuters · 1d ago
TG Therapeutics Announces Commercial Launch Of BRIUMVI For The Treatment Of Adult Patients With Relapsing Forms Of Multiple Sclerosis
Benzinga · 1d ago
TG Therapeutics Commercially Launches Multiple Sclerosis Drug
TG Therapeutics Commercially Launches Multiple Sclerosis Drug
MT Newswires · 1d ago
TG Therapeutics nears one-year high
Seeking Alpha · 3d ago
The Latest Analyst Ratings for TG Therapeutics
Benzinga · 3d ago
More
About TGTX
TG Therapeutics, Inc. (TG) is a fully integrated, commercial stage biopharmaceutical company, which is focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. Its pipeline candidates include TG-1501 (Cosibelimab), TG-1701 (BTK inhibitor), TG-1801 (anti-CD47/anti-CD19 bispecific monoclonal antibody). Its UKONIQ (umbralisib) is developed for the treatment of adult patients with relapsed or refractory marginal zone lymphoma who have received at least one prior anti-CD20-based regimen and relapsed or refractory follicular lymphoma. It has three programs in Phase III development for the treatment of patients with relapsing forms of multiple sclerosis and patients with chronic lymphocytic leukemia and several investigational medicines in Phase I clinical development. It also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition and/or investment opportunities.

Webull offers kinds of TG Therapeutics Inc stock information, including NASDAQ:TGTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TGTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TGTX stock methods without spending real money on the virtual paper trading platform.